Feature Article | Why Leen Kawas is Prioritizing Strategic Leadership at Propel Bio Partners

With biotech venture funding far tighter than it was in the 2021 boom, early-stage companies are learning a hard truth: capital alone does not de-risk drug development. Leen Kawas argues that in today’s market, operational expertise, strategic guidance, and high-leverage networks are what keep promising science alive between long funding cycles. Using Propel Bio Partners’ venture partner model, including the appointment of seasoned operator Laurie Heilmann, she lays out why leadership depth, partnership readiness, and advisory infrastructure now separate the companies that survive from the ones that stall. In a downturn defined by longer runways, fewer deals, and tougher diligence, the winners are building execution capacity, not just raising checks.

Read the Full Article Here